Disclosures for "Phase 1 Study Evaluating the Safety and Tolerability of BHV-7000, a Novel, Selective Kv7.2/7.3 Potassium Channel Activator, in Healthy Adults"
-
Dr. Awsare has received personal compensation for serving as an employee of Biohaven. Dr. Awsare has stock in Biohaven.
-
Dr. Lerner has received personal compensation for serving as an employee of Biohaven Pharmaceuticals. Dr. Lerner has stock in Biohaven Pharmaceuticals.
-
Mr. Ashbrenner has received personal compensation for serving as an employee of Biohaven. Mr. Ashbrenner has received personal compensation for serving as an employee of Navitas. Mr. Ashbrenner has stock in Biohaven. An immediate family member of Mr. Ashbrenner has stock in Biohaven.
-
Ms. Sevinsky has received personal compensation for serving as an employee of Biohaven. Ms. Sevinsky has stock in Biohaven.
-
Dr. Bozik has received personal compensation for serving as an employee of Biohaven . Dr. Bozik has stock in Biohaven.
-
Dr. Dworetzky has received personal compensation for serving as an employee of Biohaven. Dr. Dworetzky has stock in Bristol-Myers Squibb. Dr. Dworetzky has received research support from NIH.
-
Mrs. Donahue has nothing to disclose.
-
Mr. Killingsworth has received personal compensation for serving as an employee of Knopp Biosciences. Mr. Killingsworth has received personal compensation for serving as an employee of Biohaven Pharmaceuticals. Mr. Killingsworth has stock in Knopp Biosciences. Mr. Killingsworth has stock in Biohaven Pharmaceuticals.
-
Dr. Francoeur has nothing to disclose.
-
Dr. Qureshi has received personal compensation for serving as an employee of Biohaven.